Labcorp Holdings Inc. $LH Shares Sold by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC lowered its position in Labcorp Holdings Inc. (NYSE:LH) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 203,823 shares of the medical research company’s stock after selling 3,138 shares during the period. Bartlett & CO. Wealth Management LLC owned about 0.25% of Labcorp worth $51,569,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Assetmark Inc. lifted its holdings in shares of Labcorp by 9.0% in the 1st quarter. Assetmark Inc. now owns 77,792 shares of the medical research company’s stock valued at $20,756,000 after buying an additional 6,419 shares during the period. Bessemer Group Inc. grew its holdings in Labcorp by 47.3% during the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock worth $154,493,000 after acquiring an additional 185,847 shares during the period. Allspring Global Investments Holdings LLC raised its position in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after acquiring an additional 22,170 shares in the last quarter. Independent Financial Group LLC purchased a new position in Labcorp in the first quarter worth $517,000. Finally, Wealthfront Advisers LLC lifted its holdings in Labcorp by 18.2% in the first quarter. Wealthfront Advisers LLC now owns 8,894 shares of the medical research company’s stock valued at $2,373,000 after acquiring an additional 1,370 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insiders Place Their Bets

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the sale, the executive vice president owned 6,746 shares in the company, valued at $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 6,991 shares of company stock worth $1,796,696. Insiders own 0.84% of the company’s stock.

Wall Street Analysts Forecast Growth

LH has been the topic of several research analyst reports. Robert W. Baird boosted their target price on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Bank of America raised their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $314.40.

Labcorp Stock Up 0.6%

LH opened at $283.63 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The company has a market cap of $23.26 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 1.87 and a beta of 0.89. Labcorp Holdings Inc. has a one year low of $241.81 and a one year high of $293.72. The business’s fifty day moving average is $266.22 and its two-hundred day moving average is $267.91.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.